Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 5, 2015
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 5, 2015

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/5/15 - A $90 million payday for Hospira CEO after sale to Pfizer [Chicago Tribune]
On Thursday, the same day that pharmaceutical giant Pfizer Inc. completed its acquisition of Hospira for $15 billion, Ball cashed in 1.4 million shares of stock, according to regulatory filings. Ball had run Hospira, a maker of injectable drugs, infusion technologies and biosimilars, since 2011. He agreed in February to sell the company to Pfizer i
9/5/15 - Drug ads include a lot of warnings probably too many, FDA says [Chicago Tribune]
She decides to have a "serious talk" with her dermatologist, who prescribes Humira, the best-selling drug in the world, made by AbbVie of North Chicago. It's a long list of warnings maybe too long, the Food and Drug Administration says. The FDA is studying whether those warnings, in broadcast and print ads, overwhelm and confuse consumers.
9/5/15 - European Medicines Agency Validates Gilead's Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir...
By a News Reporter-Staff News Editor at Marketing Weekly News Gilead Sciences, Inc. announced that the company's Marketing Authorization Application for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by
9/5/15 - Patent Issued for Substituted Piperazin-2,5-Diones as Multifunctional Bioactive Compounds (USPTO 9108931)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventor Deigin, Vladislav I., filed on December 19, 2013, was published online on August 18, 2015. The patent's assignee for patent number 9108931 is MANUS PHARMACEUTICALS LTD.. News editors obtained t
9/5/15 - Push is on to expand area's biotech workforce [Sun Sentinel]
Sept. 05 For four years, life-science entrepreneur Steve Glover used to travel every week from his home near Fort Lauderdale to San Francisco. But a year ago, he started a Weston company, Variant Pharmaceuticals, to develop potential drugs for rare diseases. By comparison, key biotech hubs employed tens of thousands: the New York- New Jersey metr
9/5/15 - Reports Summarize Pharmacy Practice Findings from School of Pharmacy (Disease-specific direct-to-consumer advertising for reminding consumers to take...
Reports Summarize Pharmacy Practice Findings from School of Pharmacy. By a News Reporter-Staff News Editor at Marketing Weekly News Data detailed on Drugs and Therapies have been presented. Our news journalists obtained a quote from the research from the School of Pharmacy, "Participants were exposed to a disease-specific DTC advertising for depr
9/4/15 - 3M and Catalent Obtain Outstanding Results in Purification and Clarification with 3M? Emphaze? AEX Hybrid Purifier
By a News Reporter-Staff News Editor at Drug Week Catalent Pharma Solutions and 3 M Purification Inc., recently investigated a novel purification approach that significantly increased the performance of the mAb purification process by enhancing the efficiency of the Protein A column. The process resulted in a substantially pharmaceutically pure..
9/4/15 - AGN Opens Wallet Yet Again, VTL Trims Workforce, First Biosimilar Launched
BASEL- ACADIA Pharmaceuticals Inc. has submitted a New Drug Application to the FDA seeking approval for NUPLAZID for the treatment of psychosis associated with Parkinson's disease. Allergan plc has opened its purse strings yet again- this time to acquire privately-held glaucoma treatment company AqueSys Inc.. In the United States, XEN45 is in late-
9/4/15 - Alexion Receives Notification of PDUFA Date Extension for Kanuma? (sebelipase alfa)
In response to a recent request from the FDA, Alexion submitted additional Chemistry, Manufacturing and Controls information. Due to the timing of this submission, the FDA extended the PDUFA date to allow additional time for review of the new information. The FDA has not asked for additional clinical data.
9/4/15 - All-out measures to be taken for elimination of spurious drugs
Advisor to Chief Minister Punjab on Health Kh Salman Rafique has said that elimination of spurious and sub-standard drugs is a vision of Chief Minister Shehbaz Sharif. He was talking to a delegation of Pakistan Pharmaceutical Manufacturers Association which called on him at Civil Secretariat, here Thursday. Salman Rafique said the government wanted
9/4/15 - Allergan to Acquire AqueSys
Allergan plc., a pharmaceutical company, has entered into an agreement to acquire AqueSys, Inc., a medical device company, in an all-cash transaction. Under the terms of the agreement, Allergan will pay USD300 million upfront payment and regulatory approval and commercialization milestone payments related to AqueSys' lead development programs, incl
9/4/15 - AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT
By a News Reporter-Staff News Editor at Drug Week AmpliPhi Biosciences Corporation, a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements.
9/4/15 - AstraZeneca - US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
Release date- 03092015- AstraZeneca today announced that the US Food and Drug Administration has approved BRILINTA tablets at a new 60 mg dose to be used in patients with a history of heart attack beyond the first year. BRILINTA is an oral antiplatelet treatment that works by inhibiting platelet activation and was first approved by the FDA in July
9/4/15 - AstraZeneca chief medical officer departing to join small biotech firm
The scientist who played a crucial role in defending AstraZeneca from a takeover by its American rival Pfizer is leaving the drug maker to join a small biotech firm. AstraZeneca s chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, while Elisabeth Bjrk, an associate professor of medicine a
9/4/15 - AstraZeneca heart disease drug gets FDA approval at 60mg
AstraZeneca received a much-needed boost when its blood-thinning drug, Brilinta, a potential blockbuster, was approved by the US health regulator for wider use. Antoine Yver, head of oncology in global medicines development at AstraZeneca, said: AZD9291 is moving through clinical development with unprecedented speed, and was recently granted US
9/4/15 - AstraZeneca heart disease drug gets wider FDA approval
AstraZeneca received a much-needed boost when its blood-thinning drug, Brilinta, a potential blockbuster, was approved by the US health regulator for wider use. Brilinta is one of the big earners AstraZeneca is counting on to offset falling sales from older bestsellers as they come off patent, such as Nexium and Crestor. Brilinta has had a bumpy ri
9/4/15 - AstraZeneca Says US FDA Approves Expanded Indication For Brilinta
LONDON- AstraZeneca PLC late on Thursday said the US Food and Drug Administration has approved its Brilinta tablets at a new 60 miligram dose to be used in patients with a history of heart attacks beyond the first year of treatment. The FTSE 100 drugmaker said that with the expanded indication Brilinta is now approved as a treatment for reducing th
9/4/15 - Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells
Blocking these immune checkpoints in vivo has shown significant effectiveness in open label placebo controlled clinical trials, resulting in the FDA approval of Bristol-Myers Squibb s Nivolumab and Merck s Pembrolizumab, both antibodies that target Programmed Cell Death 1. A major drawback of these therapeutics is the high cost, often upwards
9/4/15 - Biopharma industry of Europe lodges complaint in opposition to French law [National Iraqi News Agency (Iraq)]
The law has been drawn up specifically in response to a case involving Roche's cancer drug Avastin and Novartis' Lucentis, which is sold for the eye disorder age-related macular degeneration. For years, doctors have been prescribing Avastin instead of Lucentis for AMD because it is much cheaper and according to publicly-funded trials is as effectiv
9/4/15 - Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and Fiscal Year 2015 Financial Results on September 11, 2015
Biota Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, September 11, 2015 at 9:00 a.m. ET to review the Company's financial results for the thr
9/4/15 - BioTime Subsidiary Asterias Therapeutics Finalizes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of... [Health & Beauty Close - Up]
BioTime reported that subsidiary Asterias Biotherapeutics, a biotechnology company focused on the emerging field of regenerative medicine, reported that the third patient was successfully dosed at Chicago- based Rush University Medical Center in a Phase 1/ 2 a clinical trial evaluating activity of escalating doses of AST-OPC1 in newly injured patie
9/4/15 - BISP And Red Cross To Join Hands For The Better Health Of Beneficiaries
The collaboration between Benazir Income Support Programme, Red Cross and pharmaceutical companies in Pakistan will prove to be a milestone for the welfare and health of BISP beneficiaries. Saeed Elahi, Chairman Pakistan Red Crescent Society at BISP Headquarter. BISP may help Red Cross and pharmaceutical companies in Pakistan to coordinate their...
9/4/15 - BRIEF: Palm Beach County pharmaceutical company to go public [Sun Sentinel]
Sept. 03 Sancilio& Co., a Riviera Beach pharmaceutical manufacturer, has filed with the Securities and Exchange Commission for an initial public offering of its stock. Sancilio, which employs 175 workers, manufactures developmental drugs for local companies including women's health specialist TherapeuticsMD in Boca Raton and Variant Pharmaceutica
9/4/15 - Cancer charities condemn NHS England for axing medicines
Cancer charities have said the decision by NHS England to strike at least a dozen medicines off the list that the Cancer Drugs Fund will pay for is a hammer blow for patients that will shorten lives.. The Rarer Cancers Foundation, which campaigned to get the fund set up in 2011, said 5,500 NHS cancer patients who might have benefited from the
9/4/15 - Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond...
Raymond Dionne to its Scientific Advisory Board. By a News Reporter-Staff News Editor at Health& Medicine Week Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, announced completion of their second Phase 3 clinical study on CL-108, a novel bi-layered tablet.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement